Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha]
Mersana Therapeutics, Inc. (MRSN)
Last mersana therapeutics, inc. earnings: 2/28 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
mersana.com/about-mersana
Company Research
Source: Seeking Alpha
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Results - Earnings Call Transcript Mersana Therapeutics, Inc. (NASDAQ: MRSN Company Participants Sarah Carmody - Executive Director, Investor Relations and Corporate Communications Anna Protopapas - President, CEO & Director Dirk Huebner - Chief Medical Officer Timothy Lowinger - Chief Scientific Officer Brian DeSchuytner - SVP, Finance & Product Strategy Conference Call Participants Boris Peaker - Cowen and Company John Barrett - SVB Leerink Earl DeSouza - H.C. Wainwright & Co. Jessica Fye - JPMorgan Chase & Co. Operator Good morning, and welcome to Mersana Therapeutics Second Quarter 2019 Conference Call. [Operator Instructions]. I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed. Good morning. Welcome to Mersana's Second Quarter 2019 Conference Call. We issued a press release earlier this morning reviewing our second quarter 2019
Show less
Read more
Impact Snapshot
Event Time:
MRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRSN alerts
High impacting Mersana Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRSN
News
- Alphina Therapeutics Strengthens Management Team with Appointment of Marc Damelin, Ph.D. as Chief Scientific Officer [Yahoo! Finance]Yahoo! Finance
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $5.00 price target on the stock.MarketBeat
- Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
- Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial ResultsGlobeNewswire
- Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024GlobeNewswire
MRSN
Earnings
- 11/13/24 - Beat
MRSN
Analyst Actions
- 11/15/24 - Citigroup Inc.
MRSN
Sec Filings
- 12/26/24 - Form SCHEDULE
- 12/23/24 - Form SCHEDULE
- 12/23/24 - Form 4
- MRSN's page on the SEC website